Loading...
Very little information exists on the cost-benefit ratios of commonly used treatments for alcoholism, especially combination treatments. To make recommendations based on different economic thresholds for reimbursement, these investigators analyzed cost data from a prospective, multicenter, randomized, nine-arm, 16-week study of treatment effectiveness in 1983 patients with primary, uncomplicated alcohol dependence.
The nine treatment arms were medical management (MM) plus pharmacotherapy (naltrexone, acamprosate, both drugs, or placebo), each of these four regimens combined with a behavioral intervention (BI), and BI alone. In the outcomes study, differences between arms were small. MM plus naltrexone, with or without BI, and MM plus placebo…